The autoreactive and neuro-inflammatory disease therapy developer closed a $77.5m round co-led by Sanofi Ventures that took its total funding to more than $117m.

Sanofi Ventures, the corporate venturing arm of pharmaceutical firm Sanofi, co-led a $77.5m series B round for US-based neuro-inflammatory and autoreactive disease drug developer Escient Pharmaceuticals on Monday. The round was co-led by Cowen Healthcare Investments (CHI) and featured Osage University Partners (OUP), Redmile Group, Perceptive Advisors and all the company‚Äôs existing investors, which include…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.